EA Series Trust’s Vanda Pharmaceuticals VNDA Stock Holding History

EA Series Trust’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.02M	Buy	+155,375	New	+$996K	0.04%	603

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

EA Series Trust's VNDA Position: Q2 2023 in Review

EA Series Trust opened a new position in Vanda Pharmaceuticals (VNDA) in Q2 2023: 155,375 shares worth $1.02M. The stake represents 0.04% of the portfolio and ranks #603 among its holdings.

188 funds tracked by Wall St. Rank hold VNDA as of Q2 2023.

EA Series Trust held 155,375 shares of Vanda Pharmaceuticals worth $1.02M as of Q2 2023.
Vanda Pharmaceuticals was a new EA Series Trust position in Q2 2023.
Vanda Pharmaceuticals made up 0.04% of EA Series Trust's portfolio in Q2 2023, its #603 holding.
188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.